Pfizer and BioNTech announced their COVID-19 vaccine candidate is now 95% effective and will soon be submitted to the Food and Drug Administration for emergency use authorization.

On Wednesday, the drugmakers revealed they had completed the third phase of their vaccine and found it to be 95% effective against the coronavirus. The companies said no “serious safety concerns” were observed among the 43,000 people enrolled in the trial, with only 3.8% reporting fatigue and another 2% reporting a headache.